24-Week Canadian Study Demonstrates CBMPs Improve Patient Outcomes Using Validated Tools Across 7 Provinces

Breakthrough Findings from the 24-Week Observational Study

A groundbreaking prospective observational study conducted across seven Canadian provinces has shed new light on the efficacy of cannabis-based medicinal products (CBMPs), also known as medical cannabis, in managing chronic conditions. Published in the Canadian Journal of Pain, the research followed 276 adult patients over 24 weeks, revealing statistically significant improvements in pain, anxiety, depression, sleep duration, and overall quality of life. Led by researchers from the University of Toronto's Temerty Faculty of Medicine and other leading institutions, this real-world evidence underscores the potential role of supervised medical cannabis in everyday clinical practice.

The Medical Cannabis Real-World Evidence (MCRWE) study, supported by the University Health Network (UHN) in Toronto, allowed patients to select Health Canada-verified products under physician guidance through a national pharmacy platform like Shoppers Drug Mart. This approach mirrors real-life usage, providing valuable insights beyond controlled trials. With 85% of participants seeking relief from chronic pain—such as migraines, arthritis, cancer pain, and multiple sclerosis—the findings are particularly relevant for pain management strategies in Canada.

Study Design and Methodology

This multicenter, long-term prospective observational study enrolled patients from clinics in Ontario, Quebec, Newfoundland and Labrador, Manitoba, Saskatchewan, Alberta, and British Columbia. Participants, primarily self-referred or recommended by licensed providers, had primary indications including chronic pain (85.2%), sleep disturbances like insomnia (49.6%), anxiety/depression (36.7%), and epilepsy. The cohort reflected typical patients: mean age 48.4 years, 64.8% female.

Validated patient-reported outcome measures (PROMs) were administered at baseline (Week 0), Week 6, Week 12, and Week 24 via email with reminders. Key tools included:

• PROMIS Pain Interference Short Form 6a (scores 6–30): Measures how pain disrupts daily activities.
• Numeric Pain Rating Scale (NPRS, 0–10): Assesses pain intensity.
• Generalized Anxiety Disorder-7 (GAD-7, 0–21): Screens for anxiety severity.
• Patient Health Questionnaire-9 (PHQ-9, 0–27): Evaluates depression symptoms.
• EQ-5D-3L (0–1): Gauges health-related quality of life across mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
• Self-reported sleep duration in hourly bands (<5h, 5–6h, 6–7h, >7h).

Data analysis used generalized estimating equations (GEE) for per-protocol (completers) and intention-to-treat analyses, with statistical significance at p<0.05. The study was approved by Veritas IRB and UHN Research Ethics Board, ensuring ethical standards.

Patient Demographics and Baseline Characteristics

The diverse cohort represented Canada's healthcare landscape, with patients from urban and rural clinics. Prior to the study, most used indica (31.8%) or indica-sativa hybrids (34.9%), with THC/CBD ratios varying from 0% to over 25%. Administration methods included oral capsules/oils (54.3%), smoking/vaping (44.2%), and topicals (1.6%). This real-world flexibility highlights patient preferences in CBMP selection.

Chronic pain dominated, but comorbidities like sleep issues and mental health challenges were common, reflecting the multifaceted nature of these conditions. High retention challenges were noted, with 50.4% (139 patients) completing Week 24 assessments; dropouts (137) often cited no response to follow-up, financial burdens (7%), side effects (7%), or lack of effect (13%).

Pain Relief Outcomes: Statistically Significant Reductions

Pain was the primary focus, with marked improvements observed. At Week 24, PROMIS Pain Interference scores dropped by 4.6 points (95% CI: -6.02 to -3.17, p<0.001, n=137), indicating less disruption in daily life. NPRS pain intensity fell by 1.19 points (95% CI: -1.7 to -0.68, p<0.001, n=137). In the pain subgroup (n=218), reductions were even stronger: PROMIS -4.89 (p<0.001), NPRS -1.27 (p<0.001).

These changes, while statistically robust, did not universally meet minimal clinically important difference (MCID) thresholds (e.g., NPRS MCID ~2 points), suggesting benefits for some but calling for personalized dosing. Early gains at Weeks 6 and 12 were sustained, supporting long-term use under supervision.

Improvements in Anxiety and Depression Symptoms

Mental health outcomes were promising. GAD-7 anxiety scores decreased by 2.24 points (95% CI: -3.5 to -0.99, p<0.001, n=139), and PHQ-9 depression scores by 2.79 points (95% CI: -4.29 to -1.3, p<0.001, n=141). These align with CBMPs' modulation of the endocannabinoid system, which influences mood regulation.

For patients with anxiety/depression indications, the reductions highlight medical cannabis as an adjunct therapy, especially amid Canada's opioid crisis where non-opioid alternatives are sought. University of Toronto researchers noted these PROMs' sensitivity to change, validated in prior pain studies.

Photo by Andy Holmes on Unsplash

Sleep Duration and Quality of Life Enhancements

Sleep improved significantly (Stuart-Maxwell test, p<0.001): at Week 24, 37.5% reported >7 hours (vs. 28.4% baseline), while <5 hours dropped to 13.2% (vs. 20.8%). EQ-5D-3L quality of life rose by 0.56 points (95% CI: -0.96 to -0.16, p<0.001, n=139), reflecting broader well-being gains.

• Mobility and self-care improvements reduced daily burdens.
• Pain/discomfort and anxiety/depression domains saw the largest shifts.

These findings support CBMPs for insomnia comorbid with pain, common in Canadian chronic disease patients.

Safety Profile: Mild Adverse Events Predominant

Safety was favorable, with common side effects including dry mouth (24.5% at Week 24), daytime sleepiness (20.8%), and euphoria ('feeling high', 11.3%). Only 7% discontinued due to side effects. No serious adverse events were highlighted, reinforcing supervised use's tolerability. This contrasts recreational cannabis risks, emphasizing regulated products' role.

Clinicians from UHN monitored via the MyMedi.ca platform, enabling dose adjustments. Future studies should explore cannabinoid ratios' impact on tolerability.

Contributions from Canadian Universities and Researchers

The study's credibility stems from academic leadership. Brian Yang and Hance Clarke from U Toronto's Temerty Faculty and Pain Research Unit spearheaded it, with collaborators from U Calgary's Anesthesiology Department. UHN's Transitional Pain Service provided clinical data, bridging research and practice.

This exemplifies Canadian higher education's role in evidence-based medicine. U Toronto's pain management programs train future specialists, while such studies inform Health Canada's policies. For more on research careers, see research positions.

Clinical Implications for Canadian Healthcare

In Canada, where chronic pain affects millions amid opioid restrictions, these results support CBMPs as adjuncts. Supervised access via licensed producers ensures quality. Physicians can use PROMs for monitoring, aligning with guidelines from the Canadian Pain Society.

Provinces like Ontario and BC, with robust clinics, may expand programs. Cost savings from reduced opioids could benefit public health. Link to full study: Canadian Journal of Pain article.

Limitations and Areas for Future Research

As observational, no control group limits causality claims; self-selection and 50% dropout bias completers toward responders. Improvements fell short of MCID, warranting RCTs. Product heterogeneity (THC/CBD, routes) needs standardization.

Future U Toronto-led extensions could examine doses, long-term safety, and subgroups (e.g., cancer pain). Randomized trials across more provinces would strengthen evidence. Ongoing MCRWE recruitment signals commitment. Summary: StratCann overview.

Photo by Chelsey Faucher on Unsplash

Broader Context: Medical Cannabis Research Landscape in Canada

Since legalization, universities drive evidence. UHN's MC-RWE (mcrwe.com) pioneers real-world data. Prior studies showed short-term gains; this 24-week extension fills gaps. Amid global debates, Canada's framework—authorized access, verified products—sets standards.

Stakeholders: Patients gain options; universities advance pharmacotherapy; policymakers refine regulations. Explore opportunities at clinical research jobs.

Future Outlook and Actionable Insights

This study positions CBMPs as viable for symptom management, urging integrated care. Patients: Consult physicians for authorization. Researchers: Leverage PROMs in trials. Educators: Incorporate into curricula at institutions like U Toronto.

With sustained benefits, expanded access could transform chronic care across Canada's provinces. Stay informed via academic resources.